<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Induction of labor with oxytocin
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Induction of labor with oxytocin
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Induction of labor with oxytocin
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William Grobman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Malavika Prabhu, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 14, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Induction of labor refers to techniques for stimulating uterine contractions to accomplish delivery prior to the spontaneous onset of such contractions. Clinicians recommend induction to patients when they believe allowing the pregnancy to continue is at least as risky for the mother and/or fetus/newborn as delivery.
        </p>
        <p>
         Use of
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         for induction in patients with an unscarred uterus will be discussed here. Methods of cervical ripening and induction in patients with a scarred uterus (eg, a previous cesarean birth or other extensive transmyometrial surgery) are reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5398.html" rel="external">
          "Induction of labor: Techniques for preinduction cervical ripening"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4451.html" rel="external">
          "Cervical ripening and induction of labor after a prior cesarean birth"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H89180566">
         <span class="h1">
          PREVALENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The frequency of labor induction in the United States was 31.4 percent in 2020, more than tripling since 1990 when it was 9.5 percent [
         <a href="#rid1">
          1
         </a>
         ]. World Health Organization data, which included 373 health-care facilities in 24 countries, showed that approximately 10 percent of births involved labor induction [
         <a href="#rid2">
          2
         </a>
         ]. However, these data were from 2010; robust recent global data are not available.
        </p>
        <p class="headingAnchor" id="H238219755">
         <span class="h1">
          INDICATIONS AND CONTRAINDICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H7531323">
         <span class="h2">
          Medical and obstetric indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Delivery before the onset of spontaneous labor is indicated when the maternal/fetal risks associated with continuing the pregnancy are thought to be at least as great as the maternal/fetal/newborn risks associated with delivery [
         <a href="#rid3">
          3
         </a>
         ]. The risk of continuing the pregnancy is influenced primarily by the severity of the maternal/fetal condition and the risk of delivery is influenced primarily by the gestational age (ie, newborn risks from early birth). The relative risk rarely can be determined with precision. When delivery before the onset of spontaneous labor is desired, induction of labor and cesarean birth are the only available options. Induction is generally preferred when there are no contraindications to labor and vaginal birth, given the increased maternal risks associated with cesarean birth. (See
         <a class="local">
          'Contraindications'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4459.html" rel="external">
          "Cesarean birth: Postoperative care, complications, and long-term sequelae"
         </a>
         .)
        </p>
        <p>
         Examples of some common conditions where induction is often medically/obstetrically indicated include, but are not limited to, the following [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postterm pregnancy (see
         <a class="medical medical_review" href="/z/d/html/6749.html" rel="external">
          "Postterm pregnancy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prelabor rupture of membranes (see
         <a class="medical medical_review" href="/z/d/html/6754.html" rel="external">
          "Preterm prelabor rupture of membranes: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6757.html" rel="external">
          "Prelabor rupture of membranes at term: Management"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertensive disorders – Preeclampsia; eclampsia; HELLP syndrome (hemolysis, elevated liver enzymes, low platelets); gestational hypertension; chronic hypertension (see
         <a class="medical medical_review" href="/z/d/html/6825.html" rel="external">
          "Preeclampsia: Antepartum management and timing of delivery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1662.html" rel="external">
          "Eclampsia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6778.html" rel="external">
          "HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6805.html" rel="external">
          "Gestational hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116432.html" rel="external">
          "Chronic hypertension in pregnancy: Prenatal and postpartum care"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes (see
         <a class="medical medical_review" href="/z/d/html/4806.html" rel="external">
          "Pregestational (preexisting) diabetes mellitus: Obstetric issues and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4800.html" rel="external">
          "Gestational diabetes mellitus: Obstetric issues and management"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal growth restriction (see
         <a class="medical medical_review" href="/z/d/html/139556.html" rel="external">
          "Fetal growth restriction: Pregnancy management and outcome", section on 'Delivery'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Twins (see
         <a class="medical medical_review" href="/z/d/html/4467.html" rel="external">
          "Twin pregnancy: Labor and delivery"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chorioamnionitis (see
         <a class="medical medical_review" href="/z/d/html/6762.html" rel="external">
          "Clinical chorioamnionitis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placental abruption (see
         <a class="medical medical_review" href="/z/d/html/6803.html" rel="external">
          "Acute placental abruption: Management and long-term prognosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oligohydramnios (see
         <a class="medical medical_review" href="/z/d/html/6777.html" rel="external">
          "Oligohydramnios: Etiology, diagnosis, and management in singleton gestations"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intrahepatic cholestasis of pregnancy (see
         <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">
          "Intrahepatic cholestasis of pregnancy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alloimmunization with fetal anemia (see
         <a class="medical medical_review" href="/z/d/html/6802.html" rel="external">
          "RhD alloimmunization in pregnancy: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">
          "Management of non-RhD red blood cell alloantibodies during pregnancy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal demise (see
         <a class="medical medical_review" href="/z/d/html/6740.html" rel="external">
          "Stillbirth: Maternal care"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Some other maternal disease states and fetal anomalies also warrant labor induction. These are discussed in UpToDate topics that review management of specific maternal and fetal disorders.
        </p>
        <p class="headingAnchor" id="H10700886">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         In each of the following settings, there is general consensus that the maternal/fetal risks associated with labor and vaginal birth, and therefore induction, are greater than the risks associated with cesarean birth; therefore, induction of labor is contraindicated.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior classical or other high-risk cesarean incision (see
         <a class="medical medical_review" href="/z/d/html/4479.html" rel="external">
          "Choosing the route of delivery after cesarean birth", section on 'Prior transfundal uterine incision'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior uterine rupture (see
         <a class="medical medical_review" href="/z/d/html/4479.html" rel="external">
          "Choosing the route of delivery after cesarean birth", section on 'Prior uterine rupture or dehiscence'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior extensive complete transmural uterine incision (see
         <a class="medical medical_review" href="/z/d/html/6801.html" rel="external">
          "Uterine fibroids (leiomyomas): Issues in pregnancy", section on 'Patients with prior myomectomy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active genital herpes simplex infection (see
         <a class="medical medical_review" href="/z/d/html/8340.html" rel="external">
          "Genital herpes simplex virus infection and pregnancy", section on 'Route of delivery'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placenta previa or vasa previa (see
         <a class="medical medical_review" href="/z/d/html/6809.html" rel="external">
          "Placenta previa: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6807.html" rel="external">
          "Velamentous umbilical cord insertion and vasa previa"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Umbilical cord prolapse or persistent funic presentation (see
         <a class="medical medical_review" href="/z/d/html/4461.html" rel="external">
          "Umbilical cord prolapse"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transverse fetal lie (see
         <a class="medical medical_review" href="/z/d/html/4447.html" rel="external">
          "Transverse fetal lie"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Invasive cervical cancer (see
         <a class="medical medical_review" href="/z/d/html/4805.html" rel="external">
          "Cervical cancer in pregnancy", section on 'Considerations about delivery'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Category III fetal heart rate tracing (see
         <a class="medical medical_review" href="/z/d/html/16663.html" rel="external">
          "Intrapartum category I, II, and III fetal heart rate tracings: Management", section on 'Category III pattern: Abnormal'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3032203243">
         <span class="h2">
          Risk-reducing induction
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the past, induction of labor in low-risk patients at 39 weeks was called "elective"; however, we and others now advocate a terminology change to risk-reducing induction (also called "prophylactic induction" or "induction at 39 weeks"), given evidence that outcomes are at least as good as, if not in some cases better than, expectant management [
         <a href="#rid4">
          4-6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2340874540">
         <span class="h3">
          At 39 weeks
         </span>
        </p>
        <p class="headingAnchor" id="H1099767738">
         <span class="h4">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on randomized trials and observational studies in which patients undergoing induction at ≥39 weeks were compared with those undergoing expectant management, it appears that labor induction among low-risk patients at ≥39 weeks who have well-dated pregnancies is a reasonable option. Potential advantages include [
         <a href="#rid7">
          7-15
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduction in cesarean birth
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduction in other adverse neonatal and maternal outcomes (eg, preeclampsia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduction in macrosomia (and its consequences)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduction in stillbirth
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ability to control the time of birth when this could be important (eg, patients with a history of rapid labor or who live far from the hospital and thus risk of out-of-hospital birth)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3593492757">
         <span class="h4">
          Evidence
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the multicenter ARRIVE trial, which evaluated the perinatal and maternal consequences of planned induction of labor at 39+0 to 39+4 weeks of gestation versus expectant management in over 6100 low-risk nulliparous patients across the United States, induction resulted in [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduced risk of cesarean birth (18.6 versus 22.2 percent, relative risk [RR] 0.84, 95% CI 0.76-0.93).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduced risk of hypertensive disorders of pregnancy (9.1 versus 14.1 percent, RR 0.64, 95% CI 0.56-0.74).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduced risk of neonatal respiratory support (3.0 versus 4.2 percent, RR 0.71, 95% CI 0.55-0.93).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A statistically similar frequency of the composite outcome of perinatal death or severe neonatal complications (4.3 versus 5.4 percent, RR 0.80, 95% CI 0.64-1.00).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Planned secondary analyses of data from the ARRIVE trial found that, compared with patients assigned to expectant management, patients induced at 39 weeks had [
         <a href="#rid13">
          13-15
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fewer antepartum visits, tests, and treatments
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Longer duration on the labor and delivery unit (by approximately six to seven hours)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Shorter postpartum maternal and neonatal hospital durations
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similar total costs
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The lowest rate of cesarean birth: 17.3 percent at 39 weeks, 22 percent at 40 weeks, and 37.5 percent at 41 to 42 weeks of gestation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The lowest rate of a composite adverse perinatal outcome: 5.1 percent at 39 weeks, 5.9 percent at 40 weeks, and 8.2 percent at 41 to 42 weeks of gestation. The composite outcome included death, respiratory support, five-minute Apgar score 3 or less, hypoxic ischemic encephalopathy, seizure, sepsis, meconium aspiration syndrome, birth trauma, intracranial or subgaleal hemorrhage, or hypotension requiring vasopressor support.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Data from observational studies support the concept that risk-reducing induction of labor among nulliparous patients at 39 weeks in typical clinical settings has an effectiveness similar to the efficacy demonstrated in the ARRIVE study. For example, in a 2019 meta-analysis of six cohort studies in which the pregnancy outcomes of &gt;66,000 nulliparous patients undergoing risk-reducing labor induction at 39 weeks were compared with those of &gt;584,000 patients undergoing expectant management beyond that gestational age, risk-reducing induction was associated with a significantly lower risk of cesarean birth, maternal peripartum infection, and adverse perinatal outcomes (respiratory morbidity, intensive care unit admission, perinatal mortality) [
         <a href="#rid12">
          12
         </a>
         ]. Similar results were reported by a 2023 meta-analysis of 12 cohort studies, one cross-sectional study, and one randomized trial (ARRIVE) [
         <a href="#rid16">
          16
         </a>
         ]. The observational studies in this analysis included both nulliparous and multiparous patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long-term outcome data regarding the outcomes of children born after risk-reducing induction versus expectant management are limited. In one study, third-grade math and reading scores were similar among those born after induction at 39 weeks of gestation and those born after expectant management beyond that gestational age in a United States population [
         <a href="#rid17">
          17
         </a>
         ]. However, because inductions were for both risk-reducing and specific medical indications, these results may be biased toward the null (ie, making outcomes of expectant management appear more favorable).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a cohort study from Australia that focused specifically on risk-reducing birth at 39 weeks, developmental outcomes at four to six years of age were similar to those born after that gestational age, regardless of whether the risk-reducing delivery occurred after labor induction or scheduled cesarean [
         <a href="#rid18">
          18
         </a>
         ]. In another Australian study, the results of a literacy and numeracy test at eight years of age also were similar regardless of whether risk-reducing induction was undertaken at 39 weeks or the patient was managed expectantly [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H680633468">
         <span class="h4">
          Recommendations of selected groups
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The American College of Obstetricians and Gynecologists (ACOG) has concluded that offering risk-reducing induction of labor to low-risk nulliparous patients at ≥39+0 weeks of gestation is a reasonable option that patients and their obstetric providers should discuss, with consideration of available resources [
         <a href="#rid20">
          20
         </a>
         ]. These recommendations apply to well-dated pregnancies. ACOG recommends against risk-reducing induction of suboptimally dated pregnancies [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5391.html" rel="external">
          "Prenatal assessment of gestational age, date of delivery, and fetal weight", section on 'Suboptimally dated pregnancies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, ACOG has stated that maternal anxiety or discomfort related to normal pregnancy, the distance between the patient’s residence and the hospital, or a previous pregnancy with shoulder dystocia are not appropriate indications for early-term induction (37+0 to 38+6 weeks) [
         <a href="#rid22">
          22
         </a>
         ], although they may be appropriate reasons for induction at ≥39+0 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Society for Maternal-Fetal Medicine also concluded that it is reasonable to offer risk-reducing induction to low-risk nulliparous patients who are ≥39+0 weeks of gestation and recommended that providers who choose this approach ensure that patients meet the eligibility criteria of the ARRIVE trial [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although no large-scale trials have been performed in low-risk individuals who have had a prior vaginal birth, observational studies that have compared those induced at 39 weeks versus those undergoing expectant management have reported similar findings to the ARRIVE trial in nullips (ie, no evidence of an increased risk of cesarean birth and some evidence of improved maternal and perinatal outcomes). In one study including 3700 low-risk parous patients, induction was associated with decreased frequency of perinatal composite morbidity (4.0 versus 7.1 percent; adjusted odds ratio [aOR] 0.57, 95% CI 0.34-0.96) and cesarean births (5.1 versus 6.6 percent; aOR 0.60, 95% CI 0.37-0.97) compared with expectant management [
         <a href="#rid24">
          24
         </a>
         ]. In another study including nearly 29,000 low-risk parous patients, induction at 39 weeks was associated with a reduced risk of hypertensive disorders of pregnancy (0.9 versus 3.5 percent; aOR 0.24, 95% CI, 0.15-0.38) [
         <a href="#rid25">
          25
         </a>
         ]. In a third study including over 20,000 low-risk parous patients, induction at 39 weeks was associated with a reduced risk of cesarean birth (2.4 versus 4.6 percent; aOR 0.70, 95% CI 0.53-0.92) and the composite adverse maternal outcome (1.6 versus 3.1 percent; aOR 0.66, 95% CI 0.47-0.93) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3377638354">
         <span class="h3">
          Induction before 39 weeks
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk-reducing induction should be avoided before 39+0 weeks of gestation [
         <a href="#rid22">
          22,27
         </a>
         ]. The morbidity of birth before 37+0 weeks (ie, preterm birth) is well-established; early-term birth (37+0 to 38+6 weeks) is also associated with greater neonatal morbidity and health care utilization during the entire first year of life compared with
         <sup>
         </sup>
         birth at 39+0 to 40+6 weeks [
         <a href="#rid28">
          28-34
         </a>
         ].
        </p>
        <p>
         To emphasize the importance of avoiding risk-reducing induction before 39+0 weeks, the National Quality Forum, the Joint Commission, and the Leapfrog Group made risk-reducing delivery prior to 39+0 weeks a maternal performance measure ("the 39 week rule") and collect data from hospitals on risk-reducing deliveries performed at 37+0 to 38+6 weeks of gestation [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1088274350">
         <span class="h1">
          PREINDUCTION ASSESSMENT AND PATIENT PREPARATION
         </span>
        </p>
        <p class="headingAnchor" id="H1428610291">
         <span class="h2">
          Checklist
         </span>
         <span class="headingEndMark">
          —
         </span>
         A thorough evaluation of maternal and fetal status is important before undertaking labor induction to make sure the indication is appropriate and to confirm the absence of contraindications to labor or vaginal birth:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review the data used to estimate gestational age and date of delivery, given that gestational age is a factor that is considered in timing of induction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Determine fetal presentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Estimate fetal weight, given the risks associated with a small or large for gestational age birth weight.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform a cervical examination to decide whether a cervical ripening agent is indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review the fetal heart rate pattern to confirm that the use of ripening agents or
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         is not contraindicated.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2345045157">
         <span class="h2">
          Patient preparation and laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient preparation and laboratory tests are generally the same as in patients in spontaneous labor (which includes a review for risk factors for problems that may develop during labor and birth [eg, past history of shoulder dystocia, postpartum hemorrhage]). In addition to standard preparation,
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The indications for and alternatives to induction, planned drugs and procedures including side effects and complications, and the possibility of cesarean birth should be discussed. (See
         <a class="medical medical_review" href="/z/d/html/4445.html" rel="external">
          "Labor and delivery: Management of the normal first stage"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A ripening process is generally employed prior to administering
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         in patients with an unfavorable cervix to shorten the duration of labor. Procedures to promote cervical ripening, especially administration of prostaglandins, may initiate labor and obviate the need for oxytocin [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5398.html" rel="external">
          "Induction of labor: Techniques for preinduction cervical ripening", section on 'Prostaglandins'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          ASSESSING THE CHANCE OF A SUCCESSFUL INDUCTION
         </span>
        </p>
        <p class="headingAnchor" id="H2256705160">
         <span class="h2">
          Clinical assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The likelihood that induction will result in vaginal birth depends on both cervical and noncervical factors.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A favorable cervix is associated with a shorter duration of induction and higher likelihood of vaginal birth whereas the converse is true when the cervix is unfavorable [
         <a href="#rid37">
          37,38
         </a>
         ]. However, it should be noted that an unfavorable cervix does not mean that avoiding labor induction and managing the patient expectantly will result in a higher chance of vaginal birth; patients with unfavorable cervixes are still at increased risk for cesarean birth with expectant management, and the ARRIVE trial demonstrated that the cesarean birth rate was lower with induction regardless of cervical status.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Noncervical factors associated with a higher chance of successful induction (as well as with higher chance of vaginal birth after spontaneous labor) include [
         <a href="#rid39">
          39-42
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Multiparity
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ruptured membranes
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lower body mass index (BMI)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Taller height
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lower estimated fetal weight
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absence of comorbidities associated with placental insufficiency (eg, preeclampsia)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In preterm gestations, a study of labor induction using data from the National Institute of Child Health and Human Development Consortium on Safe Labor found that multiparity was the best predictor of vaginal birth (multiparity versus nulliparity: odds ratio [OR] 6.8, 95% CI 6.4-7.2, n = 6555 patients) [
         <a href="#rid43">
          43
         </a>
         ]. Higher gestational age also was associated with vaginal birth: Patients &lt;34 weeks of gestation were less likely to give birth vaginally than those ≥34 weeks of gestation; nevertheless, 57 percent of patients induced at 24 to 28 weeks, 54 percent of those induced at 28 to 31 weeks, and 67 percent of those induced at 31 to 34 weeks had a vaginal birth.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2415652634">
         <span class="h3">
          Bishop score
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Bishop score is the cervical assessment system most commonly used in clinical practice in the United States [
         <a href="#rid44">
          44
         </a>
         ]. Despite its limitations, it appears to be as, or more, predictive of successful induction than fetal fibronectin [
         <a href="#rid39">
          39
         </a>
         ] or sonographic measurement of cervical length [
         <a href="#rid45">
          45
         </a>
         ]. Cervical scoring systems other than the Bishop score exist but are rarely used for predicting labor outcome (eg, Fields system; Burnett, Caldor, and Friedman modifications of the Bishop system [
         <a href="#rid46">
          46
         </a>
         ]).
        </p>
        <p>
         The Bishop score is based on the station of the presenting part and four cervical characteristics: dilation, effacement, consistency, and position  (
         <a class="graphic graphic_table graphicRef65320" href="/z/d/graphic/65320.html" rel="external">
          table 1
         </a>
         ). Cervical dilation is considered to be the most important of the five scoring elements [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         There is no universally accepted threshold for a favorable or unfavorable score. Higher Bishop scores are associated with a higher chance of vaginal birth [
         <a href="#rid44">
          44,47-49
         </a>
         ], while lower Bishop scores have been associated with a higher chance of cesarean birth [
         <a href="#rid40">
          40
         </a>
         ]. Using the Bishop scoring system, most obstetricians consider a score ≥6 as favorable and a score ≤3 as unfavorable; scores of 4 or 5 are in a gray zone. If the cervix is favorable,
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         is administered without cervical ripening. If the cervix is unfavorable, cervical ripening is recommended. (See
         <a class="medical medical_review" href="/z/d/html/5398.html" rel="external">
          "Induction of labor: Techniques for preinduction cervical ripening"
         </a>
         .)
        </p>
        <p>
         Of note, a simplified Bishop scoring system appears to be as predictive as the original system. In a cohort of over 5400 nulliparas undergoing labor induction at term, only dilation, station, and effacement, which represent three of the original five characteristics comprising the Bishop score, were significantly associated with vaginal birth [
         <a href="#rid50">
          50
         </a>
         ]. For predicting successful labor induction (defined as achieving vaginal birth), a simplified Bishop score using these three components had similar or better positive predictive value (87.7 versus 87.0 percent), negative predictive value (31.3 versus 29.8 percent), positive likelihood ratio (2.3 versus 2.2), and correct classification rate (51.0 versus 47.3 percent) compared with the conventional Bishop score.
        </p>
        <p class="headingAnchor" id="H3106148818">
         <span class="h3">
          Nonprognostic factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The time of day when induction is started does not appear to be an important independent factor in success [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early administration of neuraxial analgesia does not appear to lower the chance of vaginal birth [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4469.html" rel="external">
          "Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Effects on the progress and outcome of labor'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several investigators have attempted to derive models to predict the chance that induction will result in cesarean birth [
         <a href="#rid53">
          53-56
         </a>
         ]. One group developed an
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.uphs.upenn.edu%2Flabor-induction-calculator%2F&amp;token=pxJh42vPmzWZ5HYZS%2BHEgDFX%2BF%2FfIzGe%2FA4LYrpRvxRqC74dGS0wXhqL32sWPkV5QPqOh3QaLIyW8hAFJVbKSQ%3D%3D&amp;TOPIC_ID=4476" target="_blank">
          internet-based calculator
         </a>
         to estimate this risk for patients at term with an unfavorable cervix [
         <a href="#rid53">
          53
         </a>
         ]. A different group developed a seven-variable calculator, which is also available
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fob.tools%2Fiol-calc&amp;token=NdpSsTgDrC4WgGLeB%2BHsMWtuIgTfbXk590bmpAXn9mEcvyex4G8rTtbvc6MtVKOe&amp;TOPIC_ID=4476" target="_blank">
          online
         </a>
         [
         <a href="#rid54">
          54
         </a>
         ]. A third group developed calculators for nulliparas with term and preterm pregnancies, which are available as a mobile app [
         <a href="#rid55">
          55
         </a>
         ]. The area under the curve (AUC) in an external validation cohort of the first two models was 0.75 [
         <a href="#rid54">
          54
         </a>
         ] and 0.77 [
         <a href="#rid53">
          53
         </a>
         ] in a systematic review, and these were among the three models with the best discriminative capacity [
         <a href="#rid57">
          57
         </a>
         ]. (Note: A perfect test has an AUC equal to 1.0 whereas a test that performs no better than chance would have an AUC of 0.5).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The usefulness of these calculators in clinical practice remains uncertain. The overall predictive value of the best models is modestly better than a coin toss. Also, they were developed to evaluate the chance that a cesarean might occur if an induction were undertaken and not to indicate which patients would have a higher chance of vaginal birth if they were expectantly managed rather than induced. Similarly, they may not provide information as to which patients would have lower morbidity by avoiding labor altogether. Thus, before routine introduction into clinical practice, the benefit of their use needs to be proven.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2176845816">
         <span class="h1">
          INDUCTION PROCEDURE
         </span>
        </p>
        <p class="headingAnchor" id="H896854627">
         <span class="h2">
          Uterine and fetal heart rate monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         When
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         is administered, uterine activity and fetal heart rate (FHR) should be continuously monitored so that the dose can be adjusted based on labor progress, uterine activity, and the FHR pattern.
        </p>
        <p class="headingAnchor" id="H7537379">
         <span class="h2">
          Oxytocin administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Synthetic
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         administration is the most common and proven method of labor induction [
         <a href="#rid58">
          58,59
         </a>
         ]. In a 2016 network meta-analysis of labor induction methods, use of intravenous (IV) oxytocin plus amniotomy and use of vaginal
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         were the two approaches most likely to achieve vaginal birth within 24 hours [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3852282854">
         <span class="h3">
          Pharmacology/pharmakokinetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exogenous
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         administration produces periodic uterine contractions first demonstrable at approximately 20 weeks of gestation. Myometrial responsiveness increases with advancing gestational age until 34 weeks, at which time it levels off until spontaneous labor begins, when it increases rapidly [
         <a href="#rid61">
          61
         </a>
         ]. Increases in myometrial sensitivity are due primarily to increases in myometrial oxytocin receptor binding sites [
         <a href="#rid62">
          62
         </a>
         ]. Receptor activation triggers signaling events that stimulate contractions, primarily by elevating intracellular calcium levels [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          Oxytocin
         </a>
         cannot be administered orally because the polypeptide is degraded into small, inactive forms by gastrointestinal enzymes. Thus, it is administered intravenously; via this route, its plasma half-life has been estimated to be three to six minutes [
         <a href="#rid64">
          64
         </a>
         ]. Low-dose oxytocin protocols are based on studies showing approximately 40 minutes are required for any particular dose of oxytocin to reach a steady-state concentration and maximal uterine contractile response [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="local">
          'Dose titration'
         </a>
         below.)
        </p>
        <p>
         Progress during spontaneous labor is not related to increasing
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         concentration, uterine contractions are not associated with changes in plasma oxytocin concentration, and hypocontractile labor does not appear to be the result of a deficit of oxytocin [
         <a href="#rid66">
          66
         </a>
         ]. However, variations in genes related to the oxytocin receptor appear to be associated with the amount of oxytocin required during induction and the duration of labor [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2979175555">
         <span class="h3">
          Timing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Timing of initiation of
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         administration is only an issue in patients who have received prostaglandins for cervical ripening. In such patients, oxytocin can be initiated, if indicated:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         6 to 12 hours after the final dose of
         <a class="drug drug_general" data-topicid="9368" href="/z/d/drug information/9368.html" rel="external">
          dinoprostone
         </a>
         gel
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         30 minutes after removal of
         <a class="drug drug_general" data-topicid="9368" href="/z/d/drug information/9368.html" rel="external">
          dinoprostone
         </a>
         insert
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         4 hours after the final
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         dose
        </p>
        <p>
        </p>
        <p>
         In patients who had cervical ripening with a balloon catheter,
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         can be initiated while the catheter is in place or after it has been removed. Oxytocin can also be initiated concurrently with amniotomy. (See
         <a class="local">
          'Amniotomy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5398.html" rel="external">
          "Induction of labor: Techniques for preinduction cervical ripening", section on 'Procedure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3864926648">
         <span class="h3">
          Standardized infusion regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          Oxytocin
         </a>
         is administered intravenously by an infusion pump to allow continuous, precise control of the dose administered. We suggest hospitals implement a standardized protocol to minimize errors in oxytocin administration [
         <a href="#rid68">
          68-71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4463.html" rel="external">
          "Reducing adverse obstetric outcomes through safety sciences", section on 'Oxytocin administration'
         </a>
         .)
        </p>
        <p>
         A common regimen is to make a solution of 60 units
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         in 1000 mL crystalloid (60 milliunits in one mL) to allow the infusion pump setting (mL/hour) to match the dose administered (milliunits/minute) (eg, a pump infusion rate of 1 mL/hour equals 1 milliunit/minute).
        </p>
        <p class="headingAnchor" id="H2935540969">
         <span class="h3">
          Dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          Oxytocin
         </a>
         dosing regimens vary among and within countries [
         <a href="#rid72">
          72
         </a>
         ], differing in initial dose (0.5 to 6 milliunits/minute), time period between dose increments (10 to 60 minutes), and maximum dose (16 to 64 milliunits/minute) [
         <a href="#rid68">
          68
         </a>
         ]. The regimens are categorized as either high or low dose.
        </p>
        <p class="headingAnchor" id="H1383294838">
         <span class="h4">
          High- versus low-dose regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examples of high- and low-dose
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         infusion regimens for induction or augmentation of labor are described in the table  (
         <a class="graphic graphic_table graphicRef69023" href="/z/d/graphic/69023.html" rel="external">
          table 2
         </a>
         ). Either approach is acceptable as the regimen that achieves optimal maternal and perinatal outcomes has not been identified.
        </p>
        <p>
         Available evidence is insufficient to allow a clear conclusion as to whether using a high- versus a low-dose regimen alters the cesarean birth rate or substantively alters other maternal or neonatal outcomes, although the data do suggest that the length of labor and some outcomes, such as risk of chorioamnionitis, may be lower with higher-dose regimens:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of nine randomized trials (2391 participants) comparing high- versus low-dose
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         regimens for induction of labor, using a high-dose regimen appeared to reduce the induction-to-delivery interval (mean difference in the overall group: -0.90 hours, 95% CI -2.28 to + 0.49; mean difference on sensitivity analysis limited to high quality trials: -1.94 hours, 95% CI -0.99 to -2.89), but there was no clear effect on risk for cesarean birth (RR 0.96, 95% CI 0.81-1.14) [
         <a href="#rid73">
          73
         </a>
         ]. Although high-dose regimens resulted in a higher rate of tachysystole, maternal and perinatal complication rates were similar for both regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a subsequent large randomized double-blind trial comparing high- (initial and incremental rates of 6 milliunits/min) with standard-dose (initial and incremental rates of 2 milliunits/min)
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         augmentation in 1002 nulliparous patients, the cesarean birth rate was approximately 14 percent for both groups (relative risk [RR] 1.01; 95% CI 0.75-1.37), but the high-dose group had a shorter mean labor duration (9.1 versus 10.5 hours; mean difference -1.4 hours, 95% CI -2.2 to -0.6) and lower incidence of chorioamnionitis (10.4 versus 15.6 percent; RR 0.67, 95% CI 0.48-0.92), with a trend toward less umbilical artery acidemia (RR 0.55, 95% CI 0.29-1.01) [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1773125743">
         <span class="h4">
          Dose titration
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goal
         </strong>
         – For both high- and low-dose
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         regimens, the dose is typically increased until labor progress is normal or uterine activity reaches at least 200 to 250 Montevideo units (ie, the peak strength of contractions in mmHg measured by an internal monitor multiplied by their frequency per 10 minutes). This is approximately equivalent to contractions that are at least moderately strong to palpation, occurring every two to three minutes (three to four contractions per 10 minutes), and lasting at least 60 seconds.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The occurrence of adverse effects, such as sustained FHR abnormalities or tachysystole, should lead to a dose reduction until they resolve.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maximum dose
         </strong>
         – Although many institutional regimens limit the infusion dose to no more than 40 milliunits/minute during labor with a live fetus in the third trimester, doses as high as 90 milliunits/minute have been used without adverse maternal or fetal effects in randomized trials [
         <a href="#rid75">
          75,76
         </a>
         ]. Given these data and the variability in uterine response to the medication, we favor titrating the
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         dose according to the oxytocin responsiveness of the individual patient, primarily based on their contraction and fetal heart rate patterns, without regard to an arbitrary maximum dose.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2224564251">
         <span class="h4">
          Should oxytocin be discontinued in the active phase?
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who achieve a desirable labor pattern and progress, there is no consensus about whether the
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         dose should be discontinued or continued. In a 2022 meta-analysis of randomized trials of continued versus discontinued oxytocin in the active phase of induced labor at ≥36 weeks of gestation, the risk of cesarean with discontinuation was statistically similar to that with continuation in the subgroup of patients who actually reached the active phase and thus received the intervention (RR 0.82, 95 % CI 0.60-1.10) [
         <a href="#rid77">
          77
         </a>
         ]. Furthermore, there were no between-subgroup differences in the indication for the cesarean births that were performed. Of note, the trials were marred by many sources of bias and differences in the cervical dilation (4, 5, or 6 cm) defining the onset of the active phase of labor. A subsequent open-label randomized trial that evaluated the impact of discontinuing versus continuing oxytocin during active labor (cervical dilation ≥6 cm) on neonatal morbidity found no significant difference between approaches [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         Based on available data, either discontinuation or continuation is reasonable, as long as labor is progressing and the fetal heart rate pattern is reassuring. If discontinued,
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         can be restarted if labor progress slows. If continued, continuous fetal heart rate monitoring is essential to identify potential tachysystole with fetal heart rate changes requiring discontinuation or dose reduction.
        </p>
        <p class="headingAnchor" id="H4109913152">
         <span class="h4">
          Other approaches to dosing
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          "
         </strong>
         <strong>
          Oxytocin
         </strong>
         <strong>
          rest"
         </strong>
         <strong>
          or break
         </strong>
         – We recommend not routinely stopping
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         and then restarting the infusion after a period of time for the purpose of improving labor progress. Oxytocin-induced desensitization of the oxytocin receptor has been demonstrated in vitro, but the clinical value of this finding in patients who receive prolonged oxytocin stimulation has not been demonstrated [
         <a href="#rid79">
          79-81
         </a>
         ]. Although it has been hypothesized that stopping oxytocin if labor is not progressing and then restarting the drug several hours later will improve myometrial contractility, no randomized trials have shown clear evidence of benefit of this approach.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulsatile dosing
         </strong>
         – Some investigators have described pulsatile administration of IV
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         at 6- to 10-minute intervals as it theoretically could better simulate normal labor than continuous oxytocin administration [
         <a href="#rid82">
          82,83
         </a>
         ]. However, pulsatile administration does not improve outcomes such as reducing the frequency of cesarean birth. Furthermore, the time from the start of the infusion to delivery may be longer than with continuous oxytocin administration. Pulsatile oxytocin administration requires special equipment and is rarely used in contemporary obstetric practice.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H93529084">
         <span class="h3">
          Side effects
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tachysystole
         </strong>
         – (See
         <a class="local">
          'Tachysystole'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyponatremia
         </strong>
         –
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          Oxytocin
         </a>
         has a similar structure to vasopressin (antidiuretic hormone) and can cross-react with the renal vasopressin receptor. If higher doses (eg, 50 milliunits/minute) of oxytocin are administered in large quantities (eg, over 3 liters) of hypotonic solutions (eg,
         <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">
          5 percent dextrose in water
         </a>
         [D5W]) for prolonged periods of time (≥7 hours [
         <a href="#rid84">
          84-86
         </a>
         ]), excessive water retention can occur and result in severe, symptomatic hyponatremia, similar to the syndrome of inappropriate antidiuretic hormone secretion [
         <a href="#rid87">
          87-89
         </a>
         ]. This risk may be as high as 5 percent when the conditions described above are met [
         <a href="#rid88">
          88
         </a>
         ]. Excessive oral, rather than intravenous (IV), intake of hypotonic liquids can have the same effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Symptoms of severe acute hyponatremia include headache, anorexia, nausea, vomiting, abdominal pain, lethargy, drowsiness, unconsciousness, grand mal type seizures, and potentially irreversible neurologic injury. (See
         <a class="medical medical_review" href="/z/d/html/2287.html" rel="external">
          "Manifestations of hyponatremia and hypernatremia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If water intoxication occurs,
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         and any hypotonic solutions should be stopped. Correction of hyponatremia must be performed carefully and consists of restricting water intake and careful administration of hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         if the patient is symptomatic. (See
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypotension
         </strong>
         – Because
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         relaxes vascular smooth muscle, hypotension and tachycardia can result from rapid IV injection. This has been observed at cesarean birth when large intravenous oxytocin boluses (&gt;5 units) were administered [
         <a href="#rid90">
          90-94
         </a>
         ]. In a randomized trial of 75 patients undergoing cesarean birth and assigned to one of five doses of oxytocin postpartum, the prevalence of hypotension one minute after bolus injection of 0 units of oxytocin was 7 percent (one patient), 20 to 30 percent after bolus injection of 0.5 to 3 units, and 47 percent (seven patients) after bolus injection of 5 units [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We found no reports of hypotension with use of contemporary IV
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         infusion doses for induction of labor. However, as discussed above, it is prudent to administer oxytocin for induction by infusion pump to optimally control the rate of infusion and avoid adverse cardiovascular effects (arrhythmia, myocardial infarction, hypotension), as well as tachysystole, nausea, vomiting, headache, and flushing [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pain
         </strong>
         – Whether induced labor is more painful than spontaneous labor is not well understood. The answer is not straightforward given the many factors involved in an individual's labor experience, including the physical circumstances surrounding labor (eg, frequency and strength of uterine contractions, fetal presentation), as well as individual emotional, motivational, cognitive, and social circumstances [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data from randomized trials suggest that intrapartum pain is not worse with induction than expectant management. In a randomized trial comparing over 1700 individuals with postterm inductions with a similar number of expectantly managed/monitored postterm pregnancies, the rate of use of analgesia or anesthesia was similar for both groups (approximately 91 percent) [
         <a href="#rid96">
          96
         </a>
         ]. In a more contemporary randomized trial of induction versus expectant management at 39 weeks among low-risk nulliparous individuals, the induction group had a small reduction in overall and worst pain scores during labor and more perceived control during childbirth; regional analgesia was used in the large majority of both groups and with similar frequency [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         By comparison, some observational studies have suggested a higher frequency of epidural use among individuals undergoing medically-induced labor, although in many settings its use is common regardless of how labor is initiated [
         <a href="#rid97">
          97,98
         </a>
         ]. Also, whether this finding reflects the presence of greater pain among those being induced is uncertain because of the strong likelihood of selection bias and confounding by indication (eg, those undergoing a medical induction are more likely to have medical circumstances that would predispose to recommendation of neuraxial analgesia). As with other outcomes, it is important to consider the difference between induction versus expectant management in terms of counseling regarding management choices.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prolonged QT interval
         </strong>
         –
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          Oxytocin
         </a>
         can prolong the QT interval, but the dose at which this becomes clinically relevant remains uncertain [
         <a href="#rid99">
          99-104
         </a>
         ]. There is no need to routinely screen individuals with an electrocardiogram before the use of oxytocin; however, clinicians should be aware of the potential for arrythmia in patients with known long QT syndrome [
         <a href="#rid101">
          101
         </a>
         ]. To our knowledge, torsade de pointes has not been reported in a pregnant patient receiving oxytocin. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">
          "Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7537841">
         <span class="h2">
          Amniotomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination of amniotomy and
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         administration during induction appears to shorten the time to vaginal delivery. Amniotomy may be performed as soon as the head is well apposed to the cervix; if not well apposed, it is delayed to reduce the risk of cord prolapse.
        </p>
        <p>
         In a meta-analysis of randomized trials of patients undergoing induction (four trials, 1273 patients), early amniotomy after cervical ripening shortened the interval from induction to delivery by approximately five hours (95% CI -8.12 to -1.78) and did not increase the cesarean birth rate (31.1 versus 30.9 percent, RR 1.05, 95% CI 0.71-1.56) compared with usual care (late amniotomy or spontaneous rupture of membranes) [
         <a href="#rid105">
          105
         </a>
         ]. Early amniotomy was defined as artificial rupture of the membranes soon after successful cervical ripening (eg, expulsion of Foley balloon, cervical dilation 3 cm, or favorable Bishop score); late amniotomy was defined as artificial rupture of membranes after the onset of the active phase of labor. A subsequent secondary analysis of data from &gt;2800 nulliparous patients participating in a randomized trial of term labor induction found that amniotomy after
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         initiation was associated with either lower or similar odds of cesarean birth and other adverse outcomes compared with no amniotomy [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
         Complications of amniotomy (whether "early" or "late") include rupture of a vasa previa (if present) and umbilical cord prolapse. These complications may occur at the time of spontaneous rupture of the membranes, as well. (See
         <a class="medical medical_review" href="/z/d/html/6807.html" rel="external">
          "Velamentous umbilical cord insertion and vasa previa"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4461.html" rel="external">
          "Umbilical cord prolapse"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2531218083">
         <span class="h1">
          COMPLICATIONS OF INDUCTION
         </span>
        </p>
        <p class="headingAnchor" id="H77876583">
         <span class="h2">
          Tachysystole
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – The American College of Obstetricians and Gynecologists uses the term tachysystole to describe &gt;5 contractions in 10 minutes, averaged over a 30-minute window [
         <a href="#rid107">
          107
         </a>
         ]. The presence or absence of associated fetal heart rate (FHR) changes should also be stated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When reviewing data on tachysystole, clinicians should be mindful of the different terminologies that have been used in the literature. For example, the term "uterine hyperstimulation without fetal heart rate changes" has been used to describe uterine tachysystole (&gt;5 contractions in 10 minutes for at least 30 minutes) or uterine hypersystole/hypertonus (a contraction lasting at least 2 minutes) with a normal FHR.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Frequency
         </strong>
         – The reported frequency of tachysystole associated with
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         administration varies widely. It is estimated to occur in no more than 5 percent of patients administered prostaglandin preparations for cervical ripening and is usually well tolerated and not associated with an adverse outcome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Tachysystole occurs more frequently when higher doses of
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         or prostaglandins are used [
         <a href="#rid108">
          108-111
         </a>
         ]. It is also thought to occur more often with concurrent administration of oxytocin and a prostaglandin since both drugs carry a risk of this complication, and data from human and animal studies show that prostaglandin administration increases uterine sensitivity to oxytocin [
         <a href="#rid112">
          112-116
         </a>
         ]. Although some studies have not observed a statistically significant increase in excessive uterine activity with concurrent use, this may be due to the small numbers of patients in these studies, differences in methodology (eg, uterine activity was not continuously monitored), and the relatively low frequency of adverse events [
         <a href="#rid117">
          117-121
         </a>
         ]. In one such trial, the frequency of uterine tachysystole with concurrent
         <a class="drug drug_general" data-topicid="9368" href="/z/d/drug information/9368.html" rel="external">
          dinoprostone
         </a>
         and oxytocin administration was 14 versus 5 percent with oxytocin alone [
         <a href="#rid117">
          117
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Consequences
         </strong>
         – Since uterine activity causes intermittent interruption of blood flow to the intervillous space, excessive uterine activity for a prolonged time may result in fetal hypoxemia and acidemia [
         <a href="#rid122">
          122-126
         </a>
         ]. Rarely, tachysystole causes uterine rupture; this is more likely to occur in multiparous than nulliparous patients [
         <a href="#rid109">
          109,127
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – If
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         is being infused when tachysystole occurs, the dose should be reduced or discontinued until the tachysystole resolves, even if the FHR is not suggestive of acidemia. If adverse FHR changes are present, standard interventions should be initiated [
         <a href="#rid128">
          128,129
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16663.html" rel="external">
          "Intrapartum category I, II, and III fetal heart rate tracings: Management", section on 'Approach to selected category II patterns'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16663.html" rel="external">
          "Intrapartum category I, II, and III fetal heart rate tracings: Management", section on 'General approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         is discontinued, no studies have evaluated the optimum approach to resuming the drug. One approach resumes oxytocin at one-half the last infusion dose if it has been discontinued for less than 30 minutes and at the initial infusion dose if it has been discontinued for more than 30 minutes [
         <a href="#rid130">
          130-132
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H314155342">
         <span class="h2">
          Uterine rupture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Induction has been associated with an increased relative risk of uterine rupture, but the absolute risk is very low and most cases occur in patients with a scarred uterus. (See
         <a class="medical medical_review" href="/z/d/html/14210.html" rel="external">
          "Uterine rupture: Unscarred uterus", section on 'Risk reduction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4451.html" rel="external">
          "Cervical ripening and induction of labor after a prior cesarean birth"
         </a>
         .)
        </p>
        <p>
         In a series including over 226,000 births, 12 of the 14 ruptures in patients with unscarred uteruses occurred in those exposed to
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         for induction or augmentation of labor (two of these patients were nulliparous) [
         <a href="#rid133">
          133
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3848733970">
         <span class="h2">
          Amniotic fluid embolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Induction (compared with spontaneous labor) appears to be associated with an increased risk of amniotic fluid embolism. In one retrospective series, the adjusted odds ratio was 1.8 (95% CI 1.2-2.7), but the absolute risk difference was small (10.3 per 100,000 births with medical induction versus 5.2 per 100,000 births without medical induction) [
         <a href="#rid134">
          134
         </a>
         ]. Moreover, given that patients were induced for medical indications, it is highly plausible that the amniotic fluid embolism was causally related to these indications and not the induction itself. (See
         <a class="medical medical_review" href="/z/d/html/1591.html" rel="external">
          "Amniotic fluid embolism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1132053794">
         <span class="h2">
          Other issues
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Induction of labor at term does not appear to be a risk factor for spontaneous preterm birth in the subsequent pregnancy [
         <a href="#rid135">
          135,136
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         True allergic reactions to
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         are rare [
         <a href="#rid137">
          137,138
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no consistent evidence from well-designed studies that
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         administration is associated with autism spectrum disorder or any other long-term adverse outcomes for the offspring. In a systematic review of observational studies, there was no association between oxytocin use in labor and autism, cognitive impairment, problem behavior, or attention-deficit/hyperactivity disorder in exposed offspring [
         <a href="#rid139">
          139
         </a>
         ]. Confounding by indication and ascertainment bias are among the factors that limit the findings of observational studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The best available data in this regard were reported by investigators of a nationwide Swedish epidemiologic study that found no association between labor induction and autism in offspring when adjustments were made for environmental and genetic factors shared by siblings (hazard ratio 0.99, 95% CI 0.88-1.10) [
         <a href="#rid94">
          94
         </a>
         ]. A strength of this study was that comparison of exposure-discordant births to the same patient allowed for better adjustment for unmeasured factors.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3072608263">
         <span class="h1">
          OUTCOME
         </span>
        </p>
        <p class="headingAnchor" id="H2252234954">
         <span class="h2">
          Labor progress
         </span>
         <span class="headingEndMark">
          —
         </span>
         The average duration of the latent phase of labor is longer in induced labor than in spontaneous labor. (See
         <a class="medical medical_review" href="/z/d/html/4464.html" rel="external">
          "Labor: Overview of normal and abnormal progression", section on 'Normal progression in induced labors'
         </a>
         .)
        </p>
        <p>
         Once patients who have been induced enter active labor (cervical dilation 6 cm), progression appears to be comparable to that in patients with spontaneous onset active labor [
         <a href="#rid140">
          140
         </a>
         ]. The duration of the second stage is similar in induced and spontaneous labors as well [
         <a href="#rid140">
          140-142
         </a>
         ]. Therefore, active phase and second stage protraction disorders and arrest are diagnosed and managed the same as in patients in spontaneous labor. (See
         <a class="medical medical_review" href="/z/d/html/4464.html" rel="external">
          "Labor: Overview of normal and abnormal progression"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H975264990">
         <span class="h2">
          Definition of failed induction
         </span>
         <span class="headingEndMark">
          —
         </span>
         There has not been strong consensus as to the standard for defining a failed induction. We consider a reasonable approach to reserve the term specifically for cesareans that are performed because the latent phase has continued for an extended length of time and, in the clinician's assessment, it is unlikely that the active phase will be reached or that vaginal birth will be achieved [
         <a href="#rid143">
          143
         </a>
         ]. We would not use the term for inductions in which a cesarean is performed to treat active phase protraction or arrest, prolonged second stage, nonreassuring fetal status, or a maternal indication for prompt delivery; instead we use the terms that are typically used for these indications.
        </p>
        <p>
         A workshop convened by the United States National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, and American College of Obstetricians and Gynecologists attempted to provide evidenced-based criteria for reducing the number of cesarean births performed for failed induction in the latent phase of labor. The group proposed defining failed induction as: failure to generate regular (eg, every 3 minutes) contractions and cervical change after at least 24 hours of
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         administration, with artificial membrane rupture as soon as feasible and safe [
         <a href="#rid144">
          144
         </a>
         ]. The time devoted to cervical ripening is not included when calculating the length of induction or diagnosing failed induction.
        </p>
        <p>
         Because rupture of membranes is an important factor in the duration of induced labor,
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         generally should be administered for at least 12 hours after membrane rupture before considering the continued presence of the latent phase as an indication for cesarean [
         <a href="#rid143">
          143,145-149
         </a>
         ] given the results of two analyses [
         <a href="#rid143">
          143,145
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For nulliparous patients with an unfavorable cervix, 40 percent who remained in the latent phase after 12 hours of
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         administration and membrane rupture gave birth vaginally [
         <a href="#rid145">
          145
         </a>
         ]. Of note, approximately 70 percent exited the latent phase after 6 hours of oxytocin and membrane rupture, 20 percent between 6 and 12 hours, and 5 percent remained in the latent phase more than 12 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For parous patients, the 12-hour criteria essentially eliminated failed labor induction as an indication for cesarean birth [
         <a href="#rid143">
          143
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A retrospective review of the Consortium of Safe Labor study, including over 18,000 patients, focused on neonatal morbidity and concluded that in an otherwise uncomplicated induction with membranes ruptured, after initiation of
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         , a latent phase of at least 12 hours for nulliparous and 15 hours for multiparous patients is a reasonable criterion for diagnosing a failed induction because neonatal intensive care unit admission rates increased at those thresholds [
         <a href="#rid146">
          146
         </a>
         ]. In an analysis of a multicenter cohort involving over 10,000 nulliparous patients undergoing induction of labor, 96 percent reached the active phase within 15 hours [
         <a href="#rid148">
          148
         </a>
         ]. The authors, members of the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, concluded that cesarean should not be performed in the latent phase for an indication of "failed induction" prior to at least 15 hours after oxytocin and rupture of membranes had occurred. In 2024, ACOG/SMFM advised that if the maternal and fetal status remain reassuring, oxytocin should be administered for at least 12 to 18 hours after membrane rupture before considering induction failure and individualize the decision to continue past 18 hours [
         <a href="#rid149">
          149
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1789006690">
         <span class="h1">
          LABOR INDUCTION WITHOUT INITIAL USE OF OXYTOCIN
         </span>
        </p>
        <p class="headingAnchor" id="H1461538377">
         <span class="h2">
          Amniotomy alone
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with a favorable cervix, use of amniotomy alone is an option to initiate labor if the head is well apposed to the cervix; however, the combination of amniotomy and intravenous
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         administration is more effective. In a meta-analysis of randomized trials, this combination resulted in a substantial reduction in pregnancies undelivered at 24 hours compared with amniotomy alone (2.1 versus 16.3 percent, relative risk [RR] 0.13, 95% CI 0.04-0.41; two trials with a total of 296 participants) [
         <a href="#rid150">
          150
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H509797449">
         <span class="h2">
          Prostaglandin E1 or E2
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with unfavorable cervixes, prostaglandins are a proven method of cervical ripening and may initiate labor as a result of their uterotonic effects. (See
         <a class="medical medical_review" href="/z/d/html/5398.html" rel="external">
          "Induction of labor: Techniques for preinduction cervical ripening", section on 'Prostaglandins'
         </a>
         .)
        </p>
        <p>
         In patients with favorable cervixes, however, there are inadequate data to determine the safety and efficacy of using prostaglandins instead of
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         to initiate induction of labor. Until such data are available, we avoid use of prostaglandins to induce labor in patients with favorable cervixes.
        </p>
        <p class="headingAnchor" id="H932167056">
         <span class="h2">
          Membrane stripping
         </span>
         <span class="headingEndMark">
          —
         </span>
         Membrane stripping has not been associated with demonstrable improvements in many clinically important outcomes (eg, lower cesarean rates, better perinatal outcomes), and as such, the decision to perform it should be individualized based on patient choice.
        </p>
        <p>
         Stripping or sweeping of the membranes involves inserting the examiner's finger beyond the internal cervical os and then rotating the finger circumferentially along the lower uterine segment to detach the fetal membranes from the decidua. It is typically performed during an office visit when the cervix is partially dilated and the patient and clinician hope to hasten the onset of spontaneous labor. Thus, it should be performed only in those planning a trial of labor who are at least 39 weeks.
        </p>
        <p>
         In a 2020 meta-analysis of 40 randomized trials (&gt;6500 participants) comparing membrane sweeping with no or a sham intervention, sweeping modestly reduced the rate of formal labor induction (23 versus 31 percent, RR 0.73, 95% CI 0.56-0.94) and increased the rate of spontaneous onset of labor (72 versus 60 percent, RR 1.21, 95% CI 1.08-1.34) without affecting other maternal or neonatal outcomes [
         <a href="#rid151">
          151
         </a>
         ]. Participants generally felt the benefits outweighed the harms (eg, discomfort) and would recommend it to others.
        </p>
        <p>
         Group B
         <em>
          Streptococcus
         </em>
         colonization is not a contraindication to membrane sweeping as there is no direct evidence of harm. This issue is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/438.html" rel="external">
          "Prevention of early-onset group B streptococcal disease in neonates", section on 'Antepartum procedures'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H622666387">
         <span class="h2">
          Nonstandard approaches
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a paucity of data regarding the safety and/or efficacy of glucocorticoids,
         <a class="drug drug_general" data-topicid="8846" href="/z/d/drug information/8846.html" rel="external">
          castor oil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8657" href="/z/d/drug information/8657.html" rel="external">
          hyaluronidase
         </a>
         ,
         <a class="drug drug_general" data-topicid="8581" href="/z/d/drug information/8581.html" rel="external">
          isosorbide mononitrate
         </a>
         , acupuncture, evening primrose oil, herbal preparations, breast stimulation, or sexual intercourse for labor induction, and none of these can be recommended as an evidence-based approach to labor induction [
         <a href="#rid152">
          152-162
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1452055309">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113526.html" rel="external">
          "Society guideline links: Cervical ripening and labor induction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H81827198">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16907.html" rel="external">
          "Patient education: Labor and childbirth (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for induction
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High-risk pregnancies
         </strong>
         – Induction of labor is indicated when continuation of the pregnancy is thought to be associated with maternal or fetal risks that are at least as great as (if not greater than) labor induction and there is no contraindication to vaginal birth. The risks are influenced primarily by the gestational age and severity of the maternal/fetal conditions, and can rarely be determined with precision. Some of the most common indications are postdate pregnancy, hypertensive disorders, prelabor rupture of membranes, and diabetes. (See
         <a class="local">
          'Medical and obstetric indications'
         </a>
         above and
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low-risk pregnancies
         </strong>
         – Risk-reducing induction may be offered to low-risk patients without other medical indication at 39 weeks of gestation (this has been called "elective" induction). The pregnancy should be well dated given the increased risk of neonatal complications prior to 39 weeks. The values and preferences of the pregnant patient and the resources (including personnel) available for a risk-reducing procedure need to be considered when making this decision. (See
         <a class="local">
          'Risk-reducing induction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preinduction evaluation and management
         </strong>
         – Preinduction evaluation includes reviewing the estimate of gestational age, determining fetal presentation, estimating fetal weight, performing a cervical examination to decide whether a cervical ripening agent is indicated, evaluating the fetal heart rate pattern, and reviewing the patient's pregnancy and medical history for risk factors for potential problems that may develop during labor and delivery. (See
         <a class="local">
          'Preinduction assessment and patient preparation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cervical examination/Bishop score
         </strong>
         – Cervical status immediately before
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         administration is a key factor associated with the duration of induction and likelihood of vaginal birth. The Bishop score  (
         <a class="graphic graphic_table graphicRef65320" href="/z/d/graphic/65320.html" rel="external">
          table 1
         </a>
         ) is the best available tool for assessing cervical status. There is no universally accepted definition of favorable or unfavorable cervix. Most obstetricians consider a score ≥6 as favorable and a score ≤3 as unfavorable; scores of 4 or 5 are in a gray zone. (See
         <a class="local">
          'Clinical assessment'
         </a>
         above and
         <a class="local">
          'Bishop score'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cervical ripening
         </strong>
         – For patients with unfavorable cervixes, preinduction cervical ripening increases the likelihood of a successful induction. There is no one best regimen for ripening, and both pharmacologic and mechanical approaches are reasonable choices unless a patient has a contraindication. (See
         <a class="medical medical_review" href="/z/d/html/5398.html" rel="external">
          "Induction of labor: Techniques for preinduction cervical ripening"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oxytocin
         </strong>
         <strong>
          administration
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Role of amniotomy
         </strong>
         – For patients with favorable cervixes undergoing induction, we suggest administration of
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         with amniotomy (preferably "early" rather than "late" in timing) rather than amniotomy alone (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Amniotomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          Oxytocin
         </a>
         <strong>
          dosing
         </strong>
         – Oxytocin is administered intravenously by an infusion pump to allow continuous, precise control of the dose administered. A common regimen is to make a solution of 60 units oxytocin in 1000 mL crystalloid (60 milliunits in 1 mL) to allow the infusion pump setting (mL/hour) to match the dose administered (milliunits/minute; ie, a pump infusion rate of 1 mL/hour equals 1 milliunit/minute). (See
         <a class="local">
          'Standardized infusion regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Implementation of a standardized
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         induction protocol can minimize errors in oxytocin administration. It is unclear whether using a high- versus a low-dose oxytocin regimen  (
         <a class="graphic graphic_table graphicRef69023" href="/z/d/graphic/69023.html" rel="external">
          table 2
         </a>
         ) for labor induction or augmentation results in better outcomes; either approach is acceptable. (See
         <a class="local">
          'High- versus low-dose regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We titrate the
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         dose according to the oxytocin responsiveness of the individual patient, primarily based on their contraction and fetal heart rate patterns, without regard to an arbitrary maximum dose. The dose is typically increased until labor progress is normal; however, the dose should be reduced if sustained FHR abnormalities or tachysystole occurs. (See
         <a class="local">
          'Dose titration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Side effects
         </strong>
         – The most frequent side effect of
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         is tachysystole (&gt;5 contractions in 10 minutes, averaged over a 30-minute window). Rare side effects include hyponatremia and, if administered rapidly (intravenous bolus), hypotension. (See
         <a class="local">
          'Side effects'
         </a>
         above and
         <a class="local">
          'Tachysystole'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Discontinuation in the active phase
         </strong>
         – In patients who achieve a desirable labor pattern and progress, there is no consensus about whether
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         should be discontinued or continued in the active phase, and either approach is reasonable as long as labor is progressing and the fetal heart rate pattern is reassuring. If discontinued, oxytocin can be restarted if labor progress slows. If continued, continuous FHR monitoring will identify potential tachysystole with FHR changes requiring oxytocin discontinuation or dose reduction. (See
         <a class="local">
          'Should oxytocin be discontinued in the active phase?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Labor progress
         </strong>
         – Once a patient undergoing induction has entered active labor (cervical dilation 6 cm), progression appears to be comparable to that with spontaneous active labor. The duration of the second stage is similar in induced and spontaneous labors. Therefore, active phase and second stage protraction and arrest disorders are diagnosed and managed the same as in patients in spontaneous labor. (See
         <a class="local">
          'Labor progress'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Failed induction
         </strong>
         – Failed induction is defined as failure to generate regular (eg, every 3 minutes) contractions and cervical change after at least 24 hours of
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         administration, with artificial membrane rupture as soon as feasible and safe. The time devoted to cervical ripening is not included when calculating the length of induction or diagnosing failed induction. Because rupture of membranes is an important factor in the duration of induced labor, oxytocin generally should be administered for at least 12 hours after membrane rupture before considering the induction to have failed. (See
         <a class="local">
          'Definition of failed induction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3686617142">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Deborah A Wing, MD, MBA, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Osterman MJK, Hamilton BE, Martin JA, et al. Births: Final Data for 2020. Natl Vital Stat Rep 2022; 70:1.
          </a>
         </li>
         <li class="breakAll">
          WHO Global Survey on Maternal and Perinatal Health. Induction of labour data. Geneva, World health Organization, 2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Committee on Practice Bulletins -- Obstetrics. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol 2009; 114:386. Reaffirmed 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voutsos L. Prophylactic induction. Am J Obstet Gynecol 2020; 222:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghartey J, Macones GA. 39-Week nulliparous inductions are not elective. Am J Obstet Gynecol 2020; 222:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berghella V, Al-Hafez L, Bellussi F. Induction for 39 weeks' gestation: let's call it what it is. Am J Obstet Gynecol MFM 2020; 2:100098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrenthal DB, Hoffman MK, Jiang X, Ostrum G. Neonatal outcomes after implementation of guidelines limiting elective delivery before 39 weeks of gestation. Obstet Gynecol 2011; 118:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishanina E, Rogozinska E, Thatthi T, et al. Use of labour induction and risk of cesarean delivery: a systematic review and meta-analysis. CMAJ 2014; 186:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenstein MG, Cheng YW, Snowden JM, et al. Risk of stillbirth and infant death stratified by gestational age. Obstet Gynecol 2012; 120:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen HY, Grobman WA, Blackwell SC, Chauhan SP. Neonatal and Maternal Adverse Outcomes Among Low-Risk Parous Women at 39-41 Weeks of Gestation. Obstet Gynecol 2019; 134:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grobman WA, Rice MM, Reddy UM, et al. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. N Engl J Med 2018; 379:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grobman WA, Caughey AB. Elective induction of labor at 39 weeks compared with expectant management: a meta-analysis of cohort studies. Am J Obstet Gynecol 2019; 221:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grobman WA, Sandoval G, Reddy UM, et al. Health resource utilization of labor induction versus expectant management. Am J Obstet Gynecol 2020; 222:369.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einerson BD, Nelson RE, Sandoval G, et al. Cost of Elective Labor Induction Compared With Expectant Management in Nulliparous Women. Obstet Gynecol 2020; 136:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tita ATN, Doherty L, Grobman WA, et al. Maternal and Perinatal Outcomes of Expectant Management of Full-Term, Low-Risk, Nulliparous Patients. Obstet Gynecol 2021; 137:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong J, Atkinson J, Roddy Mitchell A, et al. Comparison of Maternal Labor-Related Complications and Neonatal Outcomes Following Elective Induction of Labor at 39 Weeks of Gestation vs Expectant Management: A Systematic Review and Meta-analysis. JAMA Netw Open 2023; 6:e2313162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werner EF, Schlichting LE, Grobman WA, et al. Association of Term Labor Induction vs Expectant Management With Child Academic Outcomes. JAMA Netw Open 2020; 3:e202503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindquist A, Hastie R, Kennedy A, et al. Developmental Outcomes for Children After Elective Birth at 39 Weeks' Gestation. JAMA Pediatr 2022; 176:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yisma E, Mol BW, Lynch JW, et al. Elective labor induction vs expectant management of pregnant women at term and children's educational outcomes at 8 years of age. Ultrasound Obstet Gynecol 2021; 58:99.
          </a>
         </li>
         <li class="breakAll">
          Practice Advisory: Clinical guidance for integration of the findings of The ARRIVE Trial: Labor Induction versus Expectant Management in Low-Risk Nulliparous Women https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Clinical-guidance-for-integration-of-the-findings-of-The-ARRIVE-Trial (Accessed on August 09, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Obstetric Practice. Committee Opinion No. 688: Management of Suboptimally Dated Pregnancies. Obstet Gynecol 2017; 129:e29. Reaffirmed 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists. ACOG committee opinion no. 561: Nonmedically indicated early-term deliveries. Obstet Gynecol 2013; 121:911. Reaffirmed 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society of Maternal-Fetal (SMFM) Publications Committee. Electronic address:
           <span class="__cf_email__" data-cfemail="770702150437041a111a59180510">
            [email protected]
           </span>
           . SMFM Statement on Elective Induction of Labor in Low-Risk Nulliparous Women at Term: the ARRIVE Trial. Am J Obstet Gynecol 2019; 221:B2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinkey RG, Blanchard CT, Szychowski JM, et al. Elective Induction of Labor in the 39th Week of Gestation Compared With Expectant Management of Low-Risk Multiparous Women. Obstet Gynecol 2019; 134:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souter V, Painter I, Sitcov K, Caughey AB. Maternal and newborn outcomes with elective induction of labor at term. Am J Obstet Gynecol 2019; 220:273.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner SM, Sandoval G, Grobman WA, et al. Labor Induction at 39 Weeks Compared with Expectant Management in Low-Risk Parous Women. Am J Perinatol 2022; 39:519.
          </a>
         </li>
         <li class="breakAll">
          Main E, Oshiro B, Chagolla B, Bingham D, Dang-Kilduff L, and Kowalewski L. Elimination
of Non-medically Indicated (Elective) Deliveries Before 39 Weeks Gestational
Age. (California Maternal Quality Care Collaborative Toolkit to Transform Maternity
Care) Developed under contract #08-85012 with the California Department of Public
Health; Maternal, Child and Adolescent Health Division; First edition published by
March of Dimes, July 2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark SL, Miller DD, Belfort MA, et al. Neonatal and maternal outcomes associated with elective term delivery. Am J Obstet Gynecol 2009; 200:156.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dietz PM, Rizzo JH, England LJ, et al. Early term delivery and health care utilization in the first year of life. J Pediatr 2012; 161:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang X, Kramer MS. Variations in mortality and morbidity by gestational age among infants born at term. J Pediatr 2009; 154:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escobar GJ, Greene JD, Hulac P, et al. Rehospitalisation after birth hospitalisation: patterns among infants of all gestations. Arch Dis Child 2005; 90:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outcomes of near-term infants. Pediatrics 2004; 114:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wetta L, Tita AT. Early term births: considerations in management. Obstet Gynecol Clin North Am 2012; 39:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parikh LI, Reddy UM, Männistö T, et al. Neonatal outcomes in early term birth. Am J Obstet Gynecol 2014; 211:265.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Main EK. New perinatal quality measures from the National Quality Forum, the Joint Commission and the Leapfrog Group. Curr Opin Obstet Gynecol 2009; 21:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas J, Fairclough A, Kavanagh J, Kelly AJ. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev 2014; :CD003101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osmundson S, Ou-Yang RJ, Grobman WA. Elective induction compared with expectant management in nulliparous women with an unfavorable cervix. Obstet Gynecol 2011; 117:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osmundson SS, Ou-Yang RJ, Grobman WA. Elective induction compared with expectant management in nulliparous women with a favorable cervix. Obstet Gynecol 2010; 116:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crane JM. Factors predicting labor induction success: a critical analysis. Clin Obstet Gynecol 2006; 49:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson KS, Waters TP. Measures of success: Prediction of successful labor induction. Semin Perinatol 2015; 39:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pevzner L, Rayburn WF, Rumney P, Wing DA. Factors predicting successful labor induction with dinoprostone and misoprostol vaginal inserts. Obstet Gynecol 2009; 114:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tolcher MC, Holbert MR, Weaver AL, et al. Predicting Cesarean Delivery After Induction of Labor Among Nulliparous Women at Term. Obstet Gynecol 2015; 126:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feghali M, Timofeev J, Huang CC, et al. Preterm induction of labor: predictors of vaginal delivery and labor curves. Am J Obstet Gynecol 2015; 212:91.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BISHOP EH. PELVIC SCORING FOR ELECTIVE INDUCTION. Obstet Gynecol 1964; 24:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verhoeven CJ, Opmeer BC, Oei SG, et al. Transvaginal sonographic assessment of cervical length and wedging for predicting outcome of labor induction at term: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2013; 42:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baacke KA, Edwards RK. Preinduction cervical assessment. Clin Obstet Gynecol 2006; 49:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vrouenraets FP, Roumen FJ, Dehing CJ, et al. Bishop score and risk of cesarean delivery after induction of labor in nulliparous women. Obstet Gynecol 2005; 105:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolkman DG, Verhoeven CJ, Brinkhorst SJ, et al. The Bishop score as a predictor of labor induction success: a systematic review. Am J Perinatol 2013; 30:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teixeira C, Lunet N, Rodrigues T, Barros H. The Bishop Score as a determinant of labour induction success: a systematic review and meta-analysis. Arch Gynecol Obstet 2012; 286:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laughon SK, Zhang J, Troendle J, et al. Using a simplified Bishop score to predict vaginal delivery. Obstet Gynecol 2011; 117:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakker JJ, van der Goes BY, Pel M, et al. Morning versus evening induction of labour for improving outcomes. Cochrane Database Syst Rev 2013; :CD007707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong CA, McCarthy RJ, Sullivan JT, et al. Early compared with late neuraxial analgesia in nulliparous labor induction: a randomized controlled trial. Obstet Gynecol 2009; 113:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine LD, Downes KL, Parry S, et al. A validated calculator to estimate risk of cesarean after an induction of labor with an unfavorable cervix. Am J Obstet Gynecol 2018; 218:254.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi RM, Requarth E, Warshak CR, et al. Risk Calculator to Predict Cesarean Delivery Among Women Undergoing Induction of Labor. Obstet Gynecol 2020; 135:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawakita T, Reddy UM, Huang JC, et al. Externally Validated Prediction Model of Vaginal Delivery After Preterm Induction With Unfavorable Cervix. Obstet Gynecol 2020; 136:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernández-Martínez A, Pascual-Pedreño AI, Baño-Garnés AB, et al. Predictive model for risk of cesarean section in pregnant women after induction of labor. Arch Gynecol Obstet 2016; 293:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Jiménez N, García-Sánchez F, Hernández-Pailos R, et al. Risk of caesarean delivery in labour induction: a systematic review and external validation of predictive models. BJOG 2022; 129:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfirevic Z, Kelly AJ, Dowswell T. Intravenous oxytocin alone for cervical ripening and induction of labour. Cochrane Database Syst Rev 2009; :CD003246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfirevic Z, Keeney E, Dowswell T, et al. Which method is best for the induction of labour? A systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess 2016; 20:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfirevic Z, Keeney E, Dowswell T, et al. Methods to induce labour: a systematic review, network meta-analysis and cost-effectiveness analysis. BJOG 2016; 123:1462.
          </a>
         </li>
         <li class="breakAll">
          Calderyro-Barcia R, Sereno JA. The response of human uterus to oxytocin throughout pregnancy. In: Oxytocin, Calderyro-Barcia R, Heller H (Eds), Pergamon Press, London 1959.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in the human uterus during pregnancy and parturition. Am J Obstet Gynecol 1984; 150:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arrowsmith S, Wray S. Oxytocin: its mechanism of action and receptor signalling in the myometrium. J Neuroendocrinol 2014; 26:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rydén G, Sjöholm I. The metabolism of oxytocin in pregnant and non-pregnant women. Acta Obstet Gynecol Scand Suppl 1971; 9:Suppl 9:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seitchik J, Amico J, Robinson AG, Castillo M. Oxytocin augmentation of dysfunctional labor. IV. Oxytocin pharmacokinetics. Am J Obstet Gynecol 1984; 150:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thornton S, Davison JM, Baylis PH. Plasma oxytocin during the first and second stages of spontaneous human labour. Acta Endocrinol (Copenh) 1992; 126:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grotegut CA, Ngan E, Garrett ME, et al. The association of single-nucleotide polymorphisms in the oxytocin receptor and G protein-coupled receptor kinase 6 (GRK6) genes with oxytocin dosing requirements and labor outcomes. Am J Obstet Gynecol 2017; 217:367.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes EJ, Weinstein L. Improving patient safety and uniformity of care by a standardized regimen for the use of oxytocin. Am J Obstet Gynecol 2008; 198:622.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark S, Belfort M, Saade G, et al. Implementation of a conservative checklist-based protocol for oxytocin administration: maternal and newborn outcomes. Am J Obstet Gynecol 2007; 197:480.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman RK, Nageotte M. A protocol for use of oxytocin. Am J Obstet Gynecol 2007; 197:445.
          </a>
         </li>
         <li class="breakAll">
          International Medication Safety Network. Oxytocin Safety Interest Group. Recommendations for Global Implementation of Safe Oxytocin Use Practices. 2023.  Available at https://www.intmedsafe.net/wp-content/uploads/2023/05/IMSN-OxytocinSIG-Recommendations-2023.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daly D, Minnie KCS, Blignaut A, et al. How much synthetic oxytocin is infused during labour? A review and analysis of regimens used in 12 countries. PLoS One 2020; 15:e0227941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Budden A, Chen LJ, Henry A. High-dose versus low-dose oxytocin infusion regimens for induction of labour at term. Cochrane Database Syst Rev 2014; :CD009701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Son M, Roy A, Stetson BT, et al. High-Dose Compared With Standard-Dose Oxytocin Regimens to Augment Labor in Nulliparous Women. Obstet Gynecol 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Son M, Roy A, Grobman WA, et al. Maximum Dose Rate of Intrapartum Oxytocin Infusion and Associated Obstetric and Perinatal Outcomes. Obstet Gynecol 2023; 141:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrill DC, Zlatnik FJ. Randomized, double-masked comparison of oxytocin dosage in induction and augmentation of labor. Obstet Gynecol 1999; 94:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang D, Yang Y, Zhang X, Nie X. Continued versus discontinued oxytocin after the active phase of labor: An updated systematic review and meta-analysis. PLoS One 2022; 17:e0267461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girault A, Sentilhes L, Desbrière R, et al. Impact of discontinuing oxytocin in active labour on neonatal morbidity: an open-label, multicentre, randomised trial. Lancet 2023; 402:2091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson C, Schumann R, Zhang P, Young RC. Oxytocin-induced desensitization of the oxytocin receptor. Am J Obstet Gynecol 2003; 188:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phaneuf S, Rodríguez Liñares B, TambyRaja RL, et al. Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour. J Reprod Fertil 2000; 120:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phaneuf S, Asbóth G, Carrasco MP, et al. Desensitization of oxytocin receptors in human myometrium. Hum Reprod Update 1998; 4:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummiskey KC, Dawood MY. Induction of labor with pulsatile oxytocin. Am J Obstet Gynecol 1990; 163:1868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tribe RM, Crawshaw SE, Seed P, et al. Pulsatile versus continuous administration of oxytocin for induction and augmentation of labor: two randomized controlled trials. Am J Obstet Gynecol 2012; 206:230.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lilien AA. Oxytocin-induced water intoxication. A report of a maternal death. Obstet Gynecol 1968; 32:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilek W, Dorr P. Water intoxication and grand mal seizure due to oxytocin. Can Med Assoc J 1970; 103:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moen V, Brudin L, Rundgren M, Irestedt L. Hyponatremia complicating labour--rare or unrecognised? A prospective observational study. BJOG 2009; 116:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WHALLEY PJ, PRITCHARD JA. OXYTOCIN AND WATER INTOXICATION. JAMA 1963; 186:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feeney JG. Water intoxication and oxytocin. Br Med J (Clin Res Ed) 1982; 285:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergum D, Lonnée H, Hakli TF. Oxytocin infusion: acute hyponatraemia, seizures and coma. Acta Anaesthesiol Scand 2009; 53:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butwick AJ, Coleman L, Cohen SE, et al. Minimum effective bolus dose of oxytocin during elective Caesarean delivery. Br J Anaesth 2010; 104:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dyer RA, Butwick AJ, Carvalho B. Oxytocin for labour and caesarean delivery: implications for the anaesthesiologist. Curr Opin Anaesthesiol 2011; 24:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregory SG, Anthopolos R, Osgood CE, et al. Association of autism with induced or augmented childbirth in North Carolina Birth Record (1990-1998) and Education Research (1997-2007) databases. JAMA Pediatr 2013; 167:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vintzileos AM, Ananth CV. Does augmentation or induction of labor with oxytocin increase the risk for autism? Am J Obstet Gynecol 2013; 209:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oberg AS, D'Onofrio BM, Rickert ME, et al. Association of Labor Induction With Offspring Risk of Autism Spectrum Disorders. JAMA Pediatr 2016; 170:e160965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowe NK. The nature of labor pain. Am J Obstet Gynecol 2002; 186:S16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannah ME, Hannah WJ, Hellmann J, et al. Induction of labor as compared with serial antenatal monitoring in post-term pregnancy. A randomized controlled trial. The Canadian Multicenter Post-term Pregnancy Trial Group. N Engl J Med 1992; 326:1587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobsen LK, Haslund H, Brock C, Laursen BS. Medically induced labor: Epidural analgesia and women's perceptions of pain in early labor. Eur J Midwifery 2018; 2:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hildingsson I, Karlström A, Nystedt A. Women's experiences of induction of labour--findings from a Swedish regional study. Aust N Z J Obstet Gynaecol 2011; 51:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillon A, Leyre S, Remérand F, et al. Modification of Tp-e and QTc intervals during caesarean section under spinal anaesthesia. Anaesthesia 2010; 65:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liou SC, Chen C, Wong SY, Wong KM. Ventricular tachycardia after oxytocin injection in patients with prolonged Q-T interval syndrome--report of two cases. Acta Anaesthesiol Sin 1998; 36:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martillotti G, Talajic M, Rey E, Leduc L. Long QT syndrome in pregnancy: are vaginal delivery and use of oxytocin permitted? A case report. J Obstet Gynaecol Can 2012; 34:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uzun M, Yapar K, Uzlu E, et al. QT interval prolongation and decreased heart rates after intravenous bolus oxytocin injection in male and female conscious rabbits. Gen Physiol Biophys 2007; 26:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreifels P, Bodi I, Hornyik T, et al. Oxytocin exerts harmful cardiac repolarization prolonging effects in drug-induced LQTS. Int J Cardiol Heart Vasc 2022; 40:101001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charbit B, Funck-Brentano C, Samain E, et al. QT interval prolongation after oxytocin bolus during surgical induced abortion. Clin Pharmacol Ther 2004; 76:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Vivo V, Carbone L, Saccone G, et al. Early amniotomy after cervical ripening for induction of labor: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol 2020; 222:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battarbee AN, Sandoval G, Grobman WA, et al. Maternal and Neonatal Outcomes Associated with Amniotomy among Nulliparous Women Undergoing Labor Induction at Term. Am J Perinatol 2021; 38:e239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009; 114:192. Reaffirmed 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith JG, Merrill DC. Oxytocin for induction of labor. Clin Obstet Gynecol 2006; 49:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flannelly GM, Turner MJ, Rassmussen MJ, Strong JM. Rupture of the uterus in Dublin: An update. J Obstet Gynaecol 1993; 13:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wing DA, Ortiz-Omphroy G, Paul RH. A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. Am J Obstet Gynecol 1997; 177:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wing DA, Miller H, Parker L, et al. Misoprostol vaginal insert for successful labor induction: a randomized controlled trial. Obstet Gynecol 2011; 117:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brummer HC. Interaction of E prostaglandins and syntocinon on the pregnant human myometrium. J Obstet Gynaecol Br Commonw 1971; 78:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillespie A. Interrelationship between oxytocin (endogenous and exogenous) and prostaglandins. Adv Biosci 1973; 9:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wikland M, Lindblom B, Hammarström S, Wiqvist N. The effect of prostaglandin I on the contractility of the term pregnant human myometrium. Prostaglandins 1983; 26:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baguma-Nibasheka M, Wentworth RA, Green LR, et al. Differences in the in vitro sensitivity of ovine myometrium and mesometrium to oxytocin and prostaglandins E2 and F2alpha. Biol Reprod 1998; 58:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan WY. Uterine and placental prostaglandins and their modulation of oxytocin sensitivity and contractility in the parturient uterus. Biol Reprod 1983; 29:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan PC, Daud SA, Omar SZ. Concurrent dinoprostone and oxytocin for labor induction in term premature rupture of membranes: a randomized controlled trial. Obstet Gynecol 2009; 113:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan RA, Khan ZE, Ashraf O. Concurrent versus sequential methods for labor induction at term. Int J Gynaecol Obstet 2007; 96:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christensen FC, Tehranifar M, Gonzalez JL, et al. Randomized trial of concurrent oxytocin with a sustained-release dinoprostone vaginal insert for labor induction at term. Am J Obstet Gynecol 2002; 186:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman FH, Rayburn WF, Burks LS, et al. Patterns of uterine activity. Using oxytocin after intracervical PGE2. J Reprod Med 1997; 42:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan PC, Valiapan SD, Tay PY, Omar SZ. Concurrent oxytocin with dinoprostone pessary versus dinoprostone pessary in labour induction of nulliparas with an unfavourable cervix: a randomised placebo-controlled trial. BJOG 2007; 114:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakker PC, Kurver PH, Kuik DJ, Van Geijn HP. Elevated uterine activity increases the risk of fetal acidosis at birth. Am J Obstet Gynecol 2007; 196:313.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jonsson M, Nordén-Lindeberg S, Ostlund I, Hanson U. Acidemia at birth, related to obstetric characteristics and to oxytocin use, during the last two hours of labor. Acta Obstet Gynecol Scand 2008; 87:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson KR, James DC. Effects of oxytocin-induced uterine hyperstimulation during labor on fetal oxygen status and fetal heart rate patterns. Am J Obstet Gynecol 2008; 199:34.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peebles DM, Spencer JA, Edwards AD, et al. Relation between frequency of uterine contractions and human fetal cerebral oxygen saturation studied during labour by near infrared spectroscopy. Br J Obstet Gynaecol 1994; 101:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heuser CC, Knight S, Esplin MS, et al. Tachysystole in term labor: incidence, risk factors, outcomes, and effect on fetal heart tracings. Am J Obstet Gynecol 2013; 209:32.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catanzarite V, Cousins L, Dowling D, Daneshmand S. Oxytocin-associated rupture of an unscarred uterus in a primigravida. Obstet Gynecol 2006; 108:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma SK, Gajraj NM, Sidawi JE. Prevention of hypotension during spinal anesthesia: a comparison of intravascular administration of hetastarch versus lactated Ringer's solution. Anesth Analg 1997; 84:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pullen KM, Riley ET, Waller SA, et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. Am J Obstet Gynecol 2007; 197:414.e1.
          </a>
         </li>
         <li class="breakAll">
          www.ihs.gov/medicalprograms/mch/f/documents/Tachysystole2.pdf (Accessed on May 24, 2012).
         </li>
         <li class="breakAll">
          Care of the patient receiving oxytocin for labor induction or augmentation. University of Michigan Hospital. November 2010. obgyn.med.umich.edu/sites/obgyn.med...edu/.../ind-aug_labor.pdf (Accessed on May 24, 2012).
         </li>
         <li class="breakAll">
          mail.ny.acog.org/website/OxytocinForInduction.pdf (Accessed on May 24, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porreco RP, Clark SL, Belfort MA, et al. The changing specter of uterine rupture. Am J Obstet Gynecol 2009; 200:269.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer MS, Rouleau J, Baskett TF, et al. Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. Lancet 2006; 368:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine LD, Bogner HR, Hirshberg A, et al. Term induction of labor and subsequent preterm birth. Am J Obstet Gynecol 2014; 210:354.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sciscione A, Larkin M, O'Shea A, et al. Preinduction cervical ripening with the Foley catheter and the risk of subsequent preterm birth. Am J Obstet Gynecol 2004; 190:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjaer BN, Krøigaard M, Garvey LH. Oxytocin use during Caesarean sections in Denmark - are we getting the dose right? Acta Anaesthesiol Scand 2016; 60:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pant D, Vohra VK, Pandey SS, Sood J. Pulseless electrical activity during caesarean delivery under spinal anaesthesia: a case report of severe anaphylactic reaction to Syntocinon. Int J Obstet Anesth 2009; 18:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lønfeldt NN, Verhulst FC, Strandberg-Larsen K, et al. Assessing risk of neurodevelopmental disorders after birth with oxytocin: a systematic review and meta-analysis. Psychol Med 2019; 49:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman MK, Vahratian A, Sciscione AC, et al. Comparison of labor progression between induced and noninduced multiparous women. Obstet Gynecol 2006; 107:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vahratian A, Zhang J, Troendle JF, et al. Labor progression and risk of cesarean delivery in electively induced nulliparas. Obstet Gynecol 2005; 105:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janakiraman V, Ecker J, Kaimal AJ. Comparing the second stage in induced and spontaneous labor. Obstet Gynecol 2010; 116:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rouse DJ, Owen J, Hauth JC. Criteria for failed labor induction: prospective evaluation of a standardized protocol. Obstet Gynecol 2000; 96:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spong CY, Berghella V, Wenstrom KD, et al. Preventing the first cesarean delivery: summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, and American College of Obstetricians and Gynecologists Workshop. Obstet Gynecol 2012; 120:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rouse DJ, Weiner SJ, Bloom SL, et al. Failed labor induction: toward an objective diagnosis. Obstet Gynecol 2011; 117:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawakita T, Reddy UM, Iqbal SN, et al. Duration of Oxytocin and Rupture of the Membranes Before Diagnosing a Failed Induction of Labor. Obstet Gynecol 2016; 128:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon CE, Grobman WA. When has an induction failed? Obstet Gynecol 2005; 105:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grobman WA, Bailit J, Lai Y, et al. Defining failed induction of labor. Am J Obstet Gynecol 2018; 218:122.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           First and Second Stage Labor Management: ACOG Clinical Practice Guideline No. 8. Obstet Gynecol 2024; 143:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howarth GR, Botha DJ. Amniotomy plus intravenous oxytocin for induction of labour. Cochrane Database Syst Rev 2001; :CD003250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finucane EM, Murphy DJ, Biesty LM, et al. Membrane sweeping for induction of labour. Cochrane Database Syst Rev 2020; 2:CD000451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavanagh J, Kelly AJ, Thomas J. Breast stimulation for cervical ripening and induction of labour. Cochrane Database Syst Rev 2005; :CD003392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavanagh J, Kelly AJ, Thomas J. Corticosteroids for cervical ripening and induction of labour. Cochrane Database Syst Rev 2006; :CD003100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavanagh J, Kelly AJ, Thomas J. Hyaluronidase for cervical ripening and induction of labour. Cochrane Database Syst Rev 2006; :CD003097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavanagh J, Kelly AJ, Thomas J. Sexual intercourse for cervical ripening and induction of labour. Cochrane Database Syst Rev 2001; :CD003093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan PC, Yow CM, Omar SZ. Effect of coital activity on onset of labor in women scheduled for labor induction: a randomized controlled trial. Obstet Gynecol 2007; 110:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dove D, Johnson P. Oral evening primrose oil: its effect on length of pregnancy and selected intrapartum outcomes in low-risk nulliparous women. J Nurse Midwifery 1999; 44:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McFarlin BL, Gibson MH, O'Rear J, Harman P. A national survey of herbal preparation use by nurse-midwives for labor stimulation. Review of the literature and recommendations for practice. J Nurse Midwifery 1999; 44:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omar NS, Tan PC, Sabir N, et al. Coitus to expedite the onset of labour: a randomised trial. BJOG 2013; 120:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly AJ, Kavanagh J, Thomas J. Castor oil, bath and/or enema for cervical priming and induction of labour. Cochrane Database Syst Rev 2013; :CD003099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith CA, Crowther CA, Grant SJ. Acupuncture for induction of labour. Cochrane Database Syst Rev 2013; :CD002962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghosh A, Lattey KR, Kelly AJ. Nitric oxide donors for cervical ripening and induction of labour. Cochrane Database Syst Rev 2016; 12:CD006901.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4476 Version 166.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Births: Final Data for 2020
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Births: Final Data for 2020
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19623003" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : ACOG Practice Bulletin No. 107: Induction of labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32122538" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prophylactic induction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32473683" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : 39-Week nulliparous inductions are not elective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33345964" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Induction for 39 weeks' gestation: let's call it what it is.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22015872" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Neonatal outcomes after implementation of guidelines limiting elective delivery before 39 weeks of gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24778358" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Use of labour induction and risk of cesarean delivery: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22914394" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Risk of stillbirth and infant death stratified by gestational age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31306312" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Neonatal and Maternal Adverse Outcomes Among Low-Risk Parous Women at 39-41 Weeks of Gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30089070" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Labor Induction versus Expectant Management in Low-Risk Nulliparous Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30817905" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Elective induction of labor at 39 weeks compared with expectant management: a meta-analysis of cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31930993" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Health resource utilization of labor induction versus expectant management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32541288" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cost of Elective Labor Induction Compared With Expectant Management in Nulliparous Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33416294" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Maternal and Perinatal Outcomes of Expectant Management of Full-Term, Low-Risk, Nulliparous Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37171818" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Comparison of Maternal Labor-Related Complications and Neonatal Outcomes Following Elective Induction of Labor at 39 Weeks of Gestation vs Expectant Management: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32275323" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Association of Term Labor Induction vs Expectant Management With Child Academic Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35532925" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Developmental Outcomes for Children After Elective Birth at 39 Weeks' Gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33030765" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Elective labor induction vs expectant management of pregnant women at term and children's educational outcomes at 8 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33030765" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Elective labor induction vs expectant management of pregnant women at term and children's educational outcomes at 8 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28225423" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Committee Opinion No. 688: Management of Suboptimally Dated Pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23635710" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : ACOG committee opinion no. 561: Nonmedically indicated early-term deliveries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30098985" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : SMFM Statement on Elective Induction of Labor in Low-Risk Nulliparous Women at Term: the ARRIVE Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31306328" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Elective Induction of Labor in the 39th Week of Gestation Compared With Expectant Management of Low-Risk Multiparous Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30716284" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Maternal and newborn outcomes with elective induction of labor at term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32916751" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Labor Induction at 39 Weeks Compared with Expectant Management in Low-Risk Parous Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32916751" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Labor Induction at 39 Weeks Compared with Expectant Management in Low-Risk Parous Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19110225" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Neonatal and maternal outcomes associated with elective term delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22421263" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Early term delivery and health care utilization in the first year of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18950794" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Variations in mortality and morbidity by gestational age among infants born at term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15665162" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Rehospitalisation after birth hospitalisation: patterns among infants of all gestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15286219" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical outcomes of near-term infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22370110" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Early term births: considerations in management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24631438" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Neonatal outcomes in early term birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19797948" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : New perinatal quality measures from the National Quality Forum, the Joint Commission and the Leapfrog Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24941907" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21343761" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Elective induction compared with expectant management in nulliparous women with an unfavorable cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733441" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Elective induction compared with expectant management in nulliparous women with a favorable cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16885664" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Factors predicting labor induction success: a critical analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26341066" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Measures of success: Prediction of successful labor induction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19622986" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Factors predicting successful labor induction with dinoprostone and misoprostol vaginal inserts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26444107" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Predicting Cesarean Delivery After Induction of Labor Among Nulliparous Women at Term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25068566" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Preterm induction of labor: predictors of vaginal delivery and labor curves.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14199536" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : PELVIC SCORING FOR ELECTIVE INDUCTION.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23533137" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Transvaginal sonographic assessment of cervical length and wedging for predicting outcome of labor induction at term: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16885663" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Preinduction cervical assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15802392" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Bishop score and risk of cesarean delivery after induction of labor in nulliparous women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23283806" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The Bishop score as a predictor of labor induction success: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22546948" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The Bishop Score as a determinant of labour induction success: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21383643" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Using a simplified Bishop score to predict vaginal delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23450578" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Morning versus evening induction of labour for improving outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19384122" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Early compared with late neuraxial analgesia in nulliparous labor induction: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29224730" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A validated calculator to estimate risk of cesarean after an induction of labor with an unfavorable cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32028500" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Risk Calculator to Predict Cesarean Delivery Among Women Undergoing Induction of Labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32925613" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Externally Validated Prediction Model of Vaginal Delivery After Preterm Induction With Unfavorable Cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26305030" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Predictive model for risk of cesarean section in pregnant women after induction of labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34559942" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Risk of caesarean delivery in labour induction: a systematic review and external validation of predictive models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19821304" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Intravenous oxytocin alone for cervical ripening and induction of labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27587290" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Which method is best for the induction of labour? A systematic review, network meta-analysis and cost-effectiveness analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27001034" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Methods to induce labour: a systematic review, network meta-analysis and cost-effectiveness analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27001034" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Methods to induce labour: a systematic review, network meta-analysis and cost-effectiveness analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6093538" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Oxytocin receptors in the human uterus during pregnancy and parturition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24888645" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Oxytocin: its mechanism of action and receptor signalling in the myometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5287107" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The metabolism of oxytocin in pregnant and non-pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6486188" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Oxytocin augmentation of dysfunctional labor. IV. Oxytocin pharmacokinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1621487" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Plasma oxytocin during the first and second stages of spontaneous human labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28526450" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The association of single-nucleotide polymorphisms in the oxytocin receptor and G protein-coupled receptor kinase 6 (GRK6) genes with oxytocin dosing requirements and labor outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18355786" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Improving patient safety and uniformity of care by a standardized regimen for the use of oxytocin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17980181" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Implementation of a conservative checklist-based protocol for oxytocin administration: maternal and newborn outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17980176" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A protocol for use of oxytocin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17980176" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A protocol for use of oxytocin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32722667" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : How much synthetic oxytocin is infused during labour? A review and analysis of regimens used in 12 countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25300173" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : High-dose versus low-dose oxytocin infusion regimens for induction of labour at term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : High-Dose Compared With Standard-Dose Oxytocin Regimens to Augment Labor in Nulliparous Women
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36649339" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Maximum Dose Rate of Intrapartum Oxytocin Infusion and Associated Obstetric and Perinatal Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10472877" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Randomized, double-masked comparison of oxytocin dosage in induction and augmentation of labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35499990" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Continued versus discontinued oxytocin after the active phase of labor: An updated systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37952548" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Impact of discontinuing oxytocin in active labour on neonatal morbidity: an open-label, multicentre, randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12592262" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Oxytocin-induced desensitization of the oxytocin receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11006150" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10027616" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Desensitization of oxytocin receptors in human myometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2256497" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Induction of labor with pulsatile oxytocin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22206748" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Pulsatile versus continuous administration of oxytocin for induction and augmentation of labor: two randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5742098" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Oxytocin-induced water intoxication. A report of a maternal death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4988877" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Water intoxication and grand mal seizure due to oxytocin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19175600" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Hyponatremia complicating labour--rare or unrecognised? A prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14059043" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : OXYTOCIN AND WATER INTOXICATION.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6807433" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Water intoxication and oxytocin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19397503" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Oxytocin infusion: acute hyponatraemia, seizures and coma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20150347" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Minimum effective bolus dose of oxytocin during elective Caesarean delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21415725" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Oxytocin for labour and caesarean delivery: implications for the anaesthesiologist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23938610" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Association of autism with induced or augmented childbirth in North Carolina Birth Record (1990-1998) and Education Research (1997-2007) databases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24071440" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Does augmentation or induction of labor with oxytocin increase the risk for autism?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27454803" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Association of Labor Induction With Offspring Risk of Autism Spectrum Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12011870" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The nature of labor pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1584259" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Induction of labor as compared with serial antenatal monitoring in post-term pregnancy. A randomized controlled trial. The Canadian Multicenter Post-term Pregnancy Trial Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33537576" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Medically induced labor: Epidural analgesia and women's perceptions of pain in early labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21466518" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Women's experiences of induction of labour--findings from a Swedish regional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20136804" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Modification of Tp-e and QTc intervals during caesarean section under spinal anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9807850" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Ventricular tachycardia after oxytocin injection in patients with prolonged Q-T interval syndrome--report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23231845" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Long QT syndrome in pregnancy: are vaginal delivery and use of oxytocin permitted? A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18063843" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : QT interval prolongation and decreased heart rates after intravenous bolus oxytocin injection in male and female conscious rabbits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35391783" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Oxytocin exerts harmful cardiac repolarization prolonging effects in drug-induced LQTS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15470335" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : QT interval prolongation after oxytocin bolus during surgical induced abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31398311" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Early amniotomy after cervical ripening for induction of labor: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32299106" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Maternal and Neonatal Outcomes Associated with Amniotomy among Nulliparous Women Undergoing Labor Induction at Term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19546798" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16885666" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Oxytocin for induction of labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Rupture of the uterus in Dublin: An update
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9322632" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21343755" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Misoprostol vaginal insert for successful labor induction: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5558314" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Interaction of E prostaglandins and syntocinon on the pregnant human myometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4805888" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Interrelationship between oxytocin (endogenous and exogenous) and prostaglandins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6396734" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : The effect of prostaglandin I on the contractility of the term pregnant human myometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9472925" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Differences in the in vitro sensitivity of ovine myometrium and mesometrium to oxytocin and prostaglandins E2 and F2alpha.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6578852" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Uterine and placental prostaglandins and their modulation of oxytocin sensitivity and contractility in the parturient uterus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19384121" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Concurrent dinoprostone and oxytocin for labor induction in term premature rupture of membranes: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17239883" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Concurrent versus sequential methods for labor induction at term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11810086" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Randomized trial of concurrent oxytocin with a sustained-release dinoprostone vaginal insert for labor induction at term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9018645" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Patterns of uterine activity. Using oxytocin after intracervical PGE2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17506788" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Concurrent oxytocin with dinoprostone pessary versus dinoprostone pessary in labour induction of nulliparas with an unfavourable cervix: a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17403401" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Elevated uterine activity increases the risk of fetal acidosis at birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18607817" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Acidemia at birth, related to obstetric characteristics and to oxytocin use, during the last two hours of labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18342288" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Effects of oxytocin-induced uterine hyperstimulation during labor on fetal oxygen status and fetal heart rate patterns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8297867" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Relation between frequency of uterine contractions and human fetal cerebral oxygen saturation studied during labour by near infrared spectroscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23571133" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Tachysystole in term labor: incidence, risk factors, outcomes, and effect on fetal heart tracings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17018478" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Oxytocin-associated rupture of an unscarred uterus in a primigravida.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8989010" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Prevention of hypotension during spinal anesthesia: a comparison of intravascular administration of hetastarch versus lactated Ringer's solution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17904983" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17904983" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17904983" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17904983" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19136093" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : The changing specter of uterine rupture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17055946" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24184339" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Term induction of labor and subsequent preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15042009" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Preinduction cervical ripening with the Foley catheter and the risk of subsequent preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26338081" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Oxytocin use during Caesarean sections in Denmark - are we getting the dose right?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19111230" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Pulseless electrical activity during caesarean delivery under spinal anaesthesia: a case report of severe anaphylactic reaction to Syntocinon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30444210" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Assessing risk of neurodevelopmental disorders after birth with oxytocin: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16648407" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Comparison of labor progression between induced and noninduced multiparous women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15802393" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Labor progression and risk of cesarean delivery in electively induced nulliparas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733442" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Comparing the second stage in induced and spontaneous labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11042299" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Criteria for failed labor induction: prospective evaluation of a standardized protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23090537" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Preventing the first cesarean delivery: summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, and American College of Obstetricians and Gynecologists Workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21252738" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Failed labor induction: toward an objective diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27400012" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Duration of Oxytocin and Rupture of the Membranes Before Diagnosing a Failed Induction of Labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15802394" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : When has an induction failed?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29138035" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Defining failed induction of labor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38096556" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : First and Second Stage Labor Management: ACOG Clinical Practice Guideline No. 8.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11687061" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Amniotomy plus intravenous oxytocin for induction of labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32103497" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Membrane sweeping for induction of labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16034897" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Breast stimulation for cervical ripening and induction of labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16625570" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Corticosteroids for cervical ripening and induction of labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16625569" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Hyaluronidase for cervical ripening and induction of labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11406072" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Sexual intercourse for cervical ripening and induction of labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17906015" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Effect of coital activity on onset of labor in women scheduled for labor induction: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10380450" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Oral evening primrose oil: its effect on length of pregnancy and selected intrapartum outcomes in low-risk nulliparous women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10380441" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : A national survey of herbal preparation use by nurse-midwives for labor stimulation. Review of the literature and recommendations for practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23145957" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Coitus to expedite the onset of labour: a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23881775" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Castor oil, bath and/or enema for cervical priming and induction of labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23945980" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Acupuncture for induction of labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27918616" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Nitric oxide donors for cervical ripening and induction of labour.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
